Hemcheck receives follow up order from its Italian distributor

SOLNA, Sweden, Nov. 22, 2022 /PRNewswire/ -- Hemcheck Sweden AB has received a small follow-up order from Levi Biotech, its Italian distributor. The order is in addition to the initial order already placed in connection with the signing of the agreement with Levi Biotech.

- It is clearly positive that we received this follow-up order as it shows the interest and need that exists. We have several ongoing product evaluations with possible customers in Italy and we hope to get addtional repeat orders, says Joen Averstad, CEO of Hemcheck.

For further information contact:

Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Email: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.

The following files are available for download: